...
首页> 外文期刊>International Journal of Chronic Obstructive Pulmonary Disease >Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
【24h】

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)

机译:格隆铵与噻托溴铵在中度至重度COPD患者中的早期支气管扩张药作用:一项交叉盲法随机研究(症状和肺功能异常)

获取原文
           

摘要

Background: Morning symptoms associated with COPD have a negative impact on patients’ quality of life. Long-acting bronchodilators with rapid onset may relieve patients’ symptoms. In the Symptoms and Pulmonary function in the moRnING study, we prospectively compared the rapid onset bronchodilator profile of glycopyrronium (GLY) and tiotropium (TIO) during the first few hours after dosing in patients with moderate-to-severe COPD. Methods: Patients were randomized (1:1) to receive either once-daily GLY (50 μg) or TIO (18?μg) and corresponding placebos in a cross-over design for 28 days. The primary objective was to demonstrate the superiority of GLY versus TIO in area under the curve from 0 to 4?hours (AUC0-4h) forced expiratory volume in 1 second (FEV1) after the first dose. The secondary objective was to compare GLY versus TIO using the patient reported outcomes Morning COPD Symptoms Questionnaire 3 hours post-inhalation. Results: One-hundred and twenty-six patients were randomized (male 70.2%; mean age 65.7?years) and 108 patients completed the study. On Day 1, GLY resulted in significantly higher FEV1 AUC0-4h after the first dose versus TIO (treatment difference [Δ], 0.030 L, 95% confidence interval 0.004–0.056, P =0.025). Improvements in morning COPD symptoms from baseline at Days 1 and 28 were similar between GLY and TIO. Post hoc analysis of the FEV1 AUC0-4h by time point on Day 1 showed significant improvements in patients receiving GLY versus TIO at 5 minutes (Δ=0.029 L, P=0.015), 15 minutes (Δ=0.033 L, P =0.026), and 1 hour (Δ=0.044 L, P =0.014). Safety results were comparable between both treatments. Conclusion: The SPRING study demonstrates the superiority of GLY versus TIO in terms of superior bronchodilation in the first 4 hours after administration, thus extending the clinical data that support a faster onset of action of GLY versus TIO.
机译:背景:与COPD相关的早晨症状对患者的生活质量有负面影响。快速起效的长效支气管扩张药可以缓解患者的症状。在moRnING研究的症状和肺功能中,我们前瞻性比较了中重度COPD患者给药后头几个小时格隆溴铵(GLY)和噻托溴铵(TIO)的快速发作支气管扩张剂分布。方法:将患者随机(1:1)接受每日一次GLY(50μg)或TIO(18?μg)和相应安慰剂的交叉设计,共28天。主要目的是证明在1秒(FEV 1 0-4h )呼气量在曲线下面积上GLY与TIO的优势。 sub>)。次要目标是使用患者在吸入后3小时报告的结果早晨COPD症状问卷对GLY与TIO进行比较。结果:126例患者被随机分组​​(男性70.2%;平均年龄65.7岁),有108例患者完成了研究。在第1天,GLY导致首次给药后的FEV 1 AUC 0-4h 显着高于TIO(治疗差异[Δ],0.030 L,95%置信区间0.004 –0.056,P = 0.025)。 GLY和TIO在第1天和第28天从基线的早晨COPD症状改善情况相似。在第1天的时间点对FEV 1 AUC 0-4h 进行事后分析表明,在5分钟时接受GLY与TIO的患者相比有显着改善(Δ= 0.029 L,P = 0.015),15分钟(Δ= 0.033 L,P = 0.026)和1小时(Δ= 0.044 L,P = 0.014)。两种治疗之间的安全性结果相当。结论:SPRING研究证明,在给药后的最初4小时内,GLY优于TIO在支气管扩张方面具有优势,从而扩展了支持GLY相对TIO更快起效的临床数据。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号